Zoran Zdraveski
General Counsel presso TSCAN THERAPEUTICS, INC.
Patrimonio netto: 37 445 $ in data 31/03/2024
Profilo
Zoran Zdraveski is currently the Secretary & Chief Legal Officer at TScan Therapeutics, Inc. He previously worked as the Vice President & Associate General Counsel at Epizyme, Inc. from 2012 to 2017 and as the Secretary & Chief Legal Officer at Magenta Therapeutics, Inc. from 2018 to 2021.
Dr. Zdraveski received his undergraduate degree from Southern Methodist University, his doctorate from Massachusetts Institute of Technology in 2002, and his graduate degree from Suffolk University Law School in 2007.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
TSCAN THERAPEUTICS, INC.
0.01% | 13/06/2023 | 4 716 ( 0.01% ) | 37 445 $ | 31/03/2024 |
Posizioni attive di Zoran Zdraveski
| Società | Posizione | Inizio |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | General Counsel | 09/09/2021 |
Precedenti posizioni note di Zoran Zdraveski
| Società | Posizione | Fine |
|---|---|---|
| MAGENTA THERAPEUTICS | General Counsel | 01/04/2021 |
| EPIZYME, INC. | Corporate Officer/Principal | 01/04/2017 |
Formazione di Zoran Zdraveski
| Southern Methodist University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
| Suffolk University Law School | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| TSCAN THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Zoran Zdraveski
